Iroko Pharmaceuticals, LLC

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

13 documents for Iroko Pharmaceuticals, LLC

- Pain Medicines in Novel Formulations Show Potential for Relief at Lower Doses.
...Iroko Pharmaceuticals Reports Phase 2 Study Results for ...
- Business Wire
- November 07, 2011
- Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nanotechnology Platform.
First Data Reported From Iroko Research Program To Build Portfolio of Lower-Dose NSAIDs PHILADELPHIA -- Iroko Pharmaceuticals, LLC today reported th...
- Business Wire
- January 06, 2011
- Iroko Pharmaceuticals Announces Financial Investment in New Product Development.
PHILADELPHIA -- Iroko Pharmaceuticals, LLC, supported by a new investment group including a private equity fund advised by Kew Capital LLP and Phoenix...
- Business Wire
- October 06, 2010

- Update: Iroko Pharmaceuticals Reports Encouraging Results from Study of Naproxen Formulated Using a Proprietary, Patented, Nano Technology Platform.
PHILADELPHIA -- Iroko Pharmaceuticals, LLC announced on January 6, 2011 the results of its Phase I clinical study of its unique formulation of naproxe...
- Business Wire
- January 26, 2011
- Iroko Divests Antibiotic Product in Canada.
...PHILADELPHIA -- Iroko Pharmaceuticals announced today the sale of its oral antibiotic pr...
- Business Wire
- May 16, 2011
- NFTE Philadelphia Announces Student Finalists for Annual Business Plan Competition.
...* Rohit C. Mehta-- Iroko Pharmaceuticals, LLC. * Carlos Moreira -- Pricewat...
- Business Wire
- June 06, 2011
- Phase 2 Results for Nano-formulated NSAIDs under Development at Iroko Pharmaceuticals to Be Reported at ACR Meeting.
PHILADELPHIA -- The results of the Phase 2 program sponsored by Iroko Pharmaceuticals to develop novel, lower-dose formulations of a widely used class...
- Business Wire
- November 04, 2011
- Iroko Pharmaceuticals Acquires Rights to Two Pharmaceutical Products from Merck & Co., Inc.
Transaction establishes Iroko in the analgesia and hypertension markets PHILADELPHIA -- Iroko Pharmaceuticals, LLC announced the acquisition of two ...
- Business Wire
- March 26, 2007
- Iroko Pharmaceuticals Appoints Susan F. Langer M.D. as Chief Medical Officer and Vice President of Research & Development.
Further senior leadership appointments made to executive team PHILADELPHIA -- Iroko Pharmaceuticals, LLC announced today the appointment of Dr. Susa...
- Business Wire
- June 07, 2007
- Iroko Pharmaceuticals Appoints John Vavricka as President and Chief Executive Officer.
Senior Management Team Formed to Lead Company Growth PHILADELPHIA -- Iroko Pharmaceuticals, LLC announced today the appointment of John Vavricka as ...
- Business Wire
- April 18, 2007